United States - English - NLM (National Library of Medicine)

contract pharmacy services-pa - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 0.25 mg - adults risperidone (risperidone) is indicated for the acute and maintenance treatment of schizophrenia [see clinical studies (14.1)]. adolescents due to janssen pharmaceuticals corporation's marketing exclusivity rights, this drug product is not labeled for use in pediatric patients with schizophrenia. pediatric use information for the treatment of pediatric patients with schizophrenia, 13 to 17 years of age, is approved for janssen pharmaceuticals corporation's risperidone drug products. monotherapy adults and pediatrics risperidone is indicated for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder in adults [see clinical studies (14.2)]. due to janssen pharmaceuticals corporation's marketing exclusivity rights, this drug product is not labeled for use in pediatric patients with bipolar mania. pediatric use information for the treatment of pediatric patients with bipolar mania, 10 to 17 years of age, is approved for janssen pharmaceuticals corporation's risperidone

United States - English - NLM (National Library of Medicine)

doh central pharmacy - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 1 mg - adults risperidone is indicated for the acute and maintenance treatment of schizophrenia [see clinical studies (14.1)] . adolescents due to janssen pharmaceuticals corporation’s marketing exclusivity rights, this drug product is not labeled for use in pediatric patients with schizophrenia. pediatric use information for the treatment of pediatric patients with schizophrenia, 13 to 17 years of age, is approved for janssen pharmaceuticals corporation’s risperidone drug products. monotherapy – adults and pediatrics risperidone is indicated for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder in adults [see clinical studies (14.2)] . due to janssen pharmaceuticals corporation’s marketing exclusivity rights, this drug product is not labeled for use in pediatric patients with bipolar mania. pediatric use information for the treatment of pediatric patients with bipolar mania, 10 to 17 years of age, is approved for janssen pharmaceuticals corporation’s risperidone drug produ

United States - English - NLM (National Library of Medicine)

contract pharmacy services-pa - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 0.25 mg - adults  risperidone tablets are indicated for the acute and maintenance treatment of schizophrenia [see clinical studies (14.1) ]. adolescents due to janssen pharmaceuticals corporation’s marketing exclusivity rights, this drug product is not labeled for use in pediatric patients with schizophrenia. pediatric use information for the treatment of pediatric patients with schizophrenia, 13 to 17 years of age, is approved for janssen pharmaceuticals corporation’s risperidone drug products. monotherapy - adults and pediatrics   risperidone tablets are indicated for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder in adults [see clinical studies (14.2) ]. due to janssen pharmaceuticals corporation’s marketing exclusivity rights, this drug product is not labeled for use in pediatric patients with bipolar mania. pediatric use information for the treatment of pediatric patients with bipolar mania, 10 to 17 years of age, is approved for janssen pharmaceuticals corporation’s r

United States - English - NLM (National Library of Medicine)

physicians total care, inc - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 0.5 mg - enter section text here adults risperidone tablets are indicated for the acute and maintenance treatment of schizophrenia [see clinical studies (14.1)]. adolescents due to janssen pharmaceuticals corporation’s marketing exclusivity rights, this drug product is not labeled for use in pediatric patients with schizophrenia .pediatric use information for the treatment of pediatric patients with schizophrenia, 13 to 17 years of age, is approved for janssen pharmaceuticals corporation’s risperidone drug products. monotherapy - adults and pediatrics risperidone tablets are indicated for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder in adults [see clinical studies (14.2)]. due to janssen pharmaceuticals corporation’s marketing exclusivity rights, this drug product is not labeled for use in pediatric patients with bipolar mania. pediatric use information for the treatment of pediatric patients with bipolar mania, 10 to 17 years of age, is approved for janssen ph

Malta - English - Medicines Authority

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - risperidone - orodispersible tablet - risperidone 0.5 milligram(s) - psycholeptics

Malta - English - Medicines Authority

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - risperidone - orodispersible tablet - risperidone 1 milligram(s) - psycholeptics

Malta - English - Medicines Authority

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - risperidone - orodispersible tablet - risperidone 2 milligram(s) - psycholeptics

Malta - English - Medicines Authority

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - risperidone - orodispersible tablet - risperidone 3 milligram(s) - psycholeptics

Malta - English - Medicines Authority

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - risperidone - orodispersible tablet - risperidone 4 milligram(s) - psycholeptics

United States - English - NLM (National Library of Medicine)

aurolife pharma llc - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 0.25 mg - risperidone tablets, usp are indicated for the treatment of irritability associated with autistic disorder in children and adolescents aged 5 to 16 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods [see clinical studies (14.4)] . pregnancy category c.  the teratogenic potential of risperidone was studied in three segment ii studies in sprague-dawley and wistar rats (0.63 to 10 mg/kg or 0.4 to 6 times the maximum recommended human dose [mrhd] on a mg/m2 basis) and in one segment ii study in new zealand rabbits (0.31 to 5 mg/kg or 0.4 to 6 times the mrhd on a mg/m2 basis). the incidence of malformations was not increased compared to control in offspring of rats or rabbits given 0.4 to 6 times the mrhd on a mg/m2 basis. in three reproductive studies in rats (two segment iii and a multigenerational study), there was an increase in pup deaths during the first 4 days of lactation at doses of 0.16 to 5 mg/kg or 0.1 to 3 times the mrhd